23 hours Ago By ABMN Staff
Marshall Wace LLP bought a new position in Savara Inc ( NASDAQ:SVRA – Free Report ) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 361,229 shares of the company’s stock, valued at approximately $1,109,000. Marshall Wace LLP owned approximately 0.
21% of Savara as of its most recent filing with the Securities and Exchange Commission (SEC). Several other hedge funds and other institutional investors have also recently made changes to their positions in SVRA. Barclays PLC lifted its stake in shares of Savara by 217.
5% in the third quarter. Barclays PLC now owns 231,005 shares of the company’s stock worth $979,000 after buying an additional 158,244 shares in the last quarter. Geode Capital Management LLC lifted its position in Savara by 10.
8% during the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock valued at $11,564,000 after purchasing an additional 264,825 shares during the period. Virtu Financial LLC bought a new position in Savara during the third quarter valued at approximately $67,000.
JPMorgan Chase & Co. lifted its position in Savara by 23.9% during the third quarter.
JPMorgan Chase & Co. now owns 69,490 shares of the company’s stock valued at $295,000 after purchasing an additional 13,420 shares during the period. Finally, SG Americas Securities LLC lifted its position in Savara by 14.
0% during the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock valued at $158,000 after purchasing an additional 6,330 shares during the period. Institutional investors own 87.
93% of the company’s stock. Savara Stock Up 2.2 % SVRA opened at $3.
26 on Wednesday. The company has a current ratio of 17.70, a quick ratio of 17.
70 and a debt-to-equity ratio of 0.13. Savara Inc has a 1-year low of $2.
26 and a 1-year high of $5.31. The company has a market capitalization of $562.
78 million, a PE ratio of -7.58 and a beta of 0.52.
The firm’s 50 day simple moving average is $2.80 and its two-hundred day simple moving average is $3.06.
Analyst Upgrades and Downgrades Separately, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Savara in a research report on Friday, March 28th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock.
According to MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.
Get Our Latest Stock Report on Savara Savara Company Profile ( Free Report ) Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001.
AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. See Also Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc ( NASDAQ:SVRA – Free Report ).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter ..
